Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2015

01-02-2015 | R&D Insight Report

Blinatumomab: First Global Approval

Author: Mark Sanford

Published in: Drugs | Issue 3/2015

Login to get access

Abstract

Blinatumomab (BLINCYTO™) is a novel, bispecific T-cell engaging antibody that binds cluster of differentiation (CD) 19 antigens on blast cells while also binding and activating the CD3/T cell receptor complex, causing cell lysis. The antibody is being developed by Amgen as a treatment for haematological cancers that originate from B cell lines. Blinatumomab was approved by the US FDA in December 2014 for the treatment of adults with Philadelphia chromosome (Ph)-negative relapsed/refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). It is awaiting approval for this indication in the EU and is in phase III development in various countries. This article summarizes the milestones in the development of blinatumomab leading to its first approval for the treatment of Ph-negative BCP-ALL.
Literature
1.
Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013;5(Suppl 1):5–11.PubMedCentralPubMed
2.
Litzow MR. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs. 2011;71:415–42.PubMed
3.
Micromet Inc. Micromet receives European Orphan Drug Designation for treatment of acute lymphoblastic leukemia with BiTE antibody blinatumomab [media release]. 3 Aug 2009. http://​www.​micromet.​de.
4.
Amgen Inc. FDA approves BLINCYTO™ (blinatumomab) immunotherapy for the treatment of relased or refractory B-cell precursor acute lymphoblastic leukemia [media release]. 3 Dec 2014. http://​www.​amgen.​com.
5.
6.
Amgen Inc. Amgen’s BiTE® immunotherapy blinatumomab receives FDA priority review designation in acute lymphoblastic leukemia [media release]. 9 Oct 2014. http://​www.​amgen.​com.
7.
8.
9.
Micromet Inc. Micromet, Inc. to regain rights to blinatumomab in North America; reports financial results for the fourth quarter and full year ended December 31, 2008 [media release]. 12 Mar 2009. http://​www.​micromet-inc.​com.
10.
11.
12.
13.
14.
15.
16.
17.
Bargou RC. Preclinical and clinical development of blinatumomab in NHL and ALL [abstract no. V888]. Oncol Res Treat. 2014;37(Supplement(5)):297.
18.
Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226–33.CrossRefPubMed
19.
Gore L, Zugmaier G, Handgretinger R, et al. Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL) [abstract no. 10007]. J Clin Oncol. 2013;31(15 Suppl 1).
20.
d’Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res. 2009;33(3):465–73.CrossRefPubMed
21.
Wong R, Pepper C, Brennan P, et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica. 2013;98(12):1930–8.CrossRefPubMedCentralPubMed
22.
Feulner J, Aigner M, Kischel R, et al. A novel CD33/CD3-bispecific BiTE antibody can effectively recruit autologous T cells from AML-patients for in vitro cell lysis of CD33+ blasts [abstract]. Cancer Res. 2012;72(8 Suppl 1).
23.
Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–8.CrossRefPubMed
24.
Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–7.CrossRefPubMed
25.
Zugmaier G, Topp MS, Alekar S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4:244.CrossRefPubMedCentralPubMed
26.
Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014. doi:10.​1200/​JCO.​2014.​56.​3247.PubMed
27.
Goekbuget N, Dombret H, Bonifacio M, et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL) [abstract no. 379]. In: 56th Annual Meeting of the American Society of Hematology; 6–9 December 2014; San Francisco.
28.
Göbeler ME, Viardot A, Noppeney R, et al. Blinatumomab (CD3/CD19 Bite®) antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL) [abstract no. V646]. Onkologie. 2011;34(suppl(6)):190–1.
29.
Goebeler ME, Viardot A, Kufer P, et al. Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory non-hodgkin’s lymphoma [abstract]. Hematol Oncol. 2013;31:197.CrossRef
30.
Viardot A, Goebeler M, Pfreundschuh M, et al. Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) [abstract no. V123]. Oncol Res Treat. 2014;37(Supplement(5)):33.
31.
Locatelli F, Gore L, Zugmaier G, et al. Blinatumomab in pediatric patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (BCP-ALL): a phase I/II study [abstract]. Bone Marrow Transpl. 2014;49:S361–2.CrossRef
32.
Whitlock J, Von Stackelberg A, Handgretinger R, et al. Blinatumomab in pediatric patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL): a phase 1/2 study [abstract]. Pediatr Blood Cancer. 2014;61:S138.
33.
Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014;99(7):1212–9.CrossRefPubMedCentralPubMed
Metadata
Title
Blinatumomab: First Global Approval
Author
Mark Sanford
Publication date
01-02-2015
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2015
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0356-3

Other articles of this Issue 3/2015

Drugs 3/2015 Go to the issue

Adis Drug Evaluation

Obinutuzumab: A Review of Its Use in Patients with Chronic Lymphocytic Leukaemia

Review Article

Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens

R&D Insight Report

Secukinumab: First Global Approval

Systematic Review

Pemphigus Vulgaris: An Evidence-Based Treatment Update

Adis Drug Evaluation

Tacrolimus Prolonged Release (Envarsus®): A Review of Its Use in Kidney and Liver Transplant Recipients

Current Opinion

Pre-Exposure Prophylaxis to Prevent HIV Infection: Current Status, Future Opportunities and Challenges